HomeAI · summaries
Storia in 4 fonti
Outlook Therapeutics Targets Multibillion Dollar Ophthalmology Market With New Drug After FDA Rejection -
The FDA approved LYTENAVA by Outlook Therapeutics, marking the first ophthalmic bevacizumab for wet AMD in the lucrative US retina market.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
medpagetoday.com
FDA Approves Branded Bevacizumab for Wet AMD
Approval follows 20 years of off-label use of compounded formulations of the VEGF inhibitor
- ·
tipranks.com
Outlook Therapeutics announces FDA approval of Lytenava for wet AMD
Outlook Therapeutics (OTLK) announced that the Food and Drug Administration has approved Lytenava for the treatment of neovascular age-related m...
